课题基金 / 基金详情

PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA

PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA
白血病的蛋白酶 3 特异性免疫治疗
批准号:
6350372
负责人:
JEFFREY J MOLLDREM
金额:
$17.72万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-04-01 至 2003-01-31

项目摘要

项目成果

JEFFREY J MOLLDREM的其他基金

相似基金

相关文献

中文摘要
翻译
在异基因骨髓移植(BMT)后,由供体淋巴细胞介导的显著的移植物抗白血病(GVL)免疫应答有助于治愈40- 50%的患有髓性白血病的成年患者。 然而,由于患者年龄和供体可用性,同种异体BMT仅适用于25%的患者。 因此,本提案的总体目标是开发产生抗原特异性抗白血病免疫应答的策略,用于治疗可应用于更多患者的髓性白血病。蛋白酶3(Pr 3)是一种26 kd的骨髓限制性嗜天青颗粒蛋白,其通常仅在发育中的早幼粒细胞中最大程度地表达,并且是韦格纳肉芽肿病患者中抗神经细胞胞质抗体(ANCA)的抗原。 Pr 3在75%的慢性髓性白血病(CML)和50%的急性髓性白血病(AML)细胞中过表达3至6倍。 来自Pr 3的HLA-A2限制性9个氨基酸肽PR 1已被证明是细胞毒性淋巴细胞(CTL)的靶表位,其在体外优先裂解髓性白血病而不是正常骨髓祖细胞。CTL裂解的量与靶细胞中的Pr 3过表达相关。 在正常供体和一些髓性白血病患者中检测到对PR 1的免疫力强烈暗示患者自身的白血病细胞可以作为免疫蛋白的来源,并回避了对PR 1的现有免疫应答是否在减缓白血病进展中发挥任何作用以及免疫应答的增强是否可以提供任何治疗益处的问题。目前的新的PRIGATOR提案将评估对PR 1肽的免疫应答的临床重要性,评估骨髓性白血病患者中基于PR 1肽的肿瘤疫苗,并且由于Pr 1是第一个确定的组织限制性表位,因此将研究其他独特的HLA-A2相关Pr 3肽作为CTL的白血病特异性表位。 为了研究PR 1免疫应答的临床意义,将使用有限稀释分析和使用荧光标记的PR 1-四聚体直接标记PR 1特异性CTL来测定CML、AML患者及其正常骨髓供体在BMT前后针对PR 1的CTL前体(CTLP)频率。 将检查白血病中的Pr 3表达和白血病的表面表型以及PR 1特异性CTL,并将其与CTLP频率和临床结果相关联。 为了研究是否可以加强对PR 1的免疫应答,I/II期研究(NCI研究编号T98-0017,Molldrem P.I.)将在CML、AML和骨髓增生异常综合征患者中进行基于PR 1肽的疫苗与不完全弗氏佐剂(IFA)的免疫接种。 德克萨斯大学M. D.安德森癌症中心已经批准了这项研究,NCI将提供GMP质量的PR 1肽和IFA。 对疫苗的免疫反应将通过CTLP的LDA以及通过用荧光PR 1四聚体分析PR 1特异性CTL的数量来确定,并将与临床反应和骨髓中白血病原始细胞的百分比相关。 最后,将研究来自Pr 3的其他合成HLA-A2相关肽在体外从供体PBMC中引发肽特异性CTL的潜力,然后测试裂解髓性白血病的能力。
英文摘要
A significant graft versus leukemia (GVL) immune response, mediated by donor lymphocytes after allogeneic bone marrow transplantation (BMT), contributes to the cure of 40-50 percent of adult patients with myeloid leukemias. However, allogeneic BMT is only available for 25 percent of all patients due to patient age and donor availability. Therefore, the overall objective of this proposal is to develop strategies for the generation of antigen-specific antileukemia immune responses for the treatment of myeloid leukemias that can be applied to more patients. Proteinase 3 (Pr3) is a 26kd myeloid-restricted azurophil granule protein that is normally maximally expressed only in developing promyelocytes and is an antigen for the antineutrophil cytoplasmic antibody (ANCA) in patients with Wegener's granulomatosis. Pr3 is overexpressed by 3 to 6 fold in 75 percent of chronic myeloid leukemia (CML) and 50 percent of acute myeloid leukemia (AML) cells. An HLA-A2-restricted 9 amino acid peptide derived from Pr3, PR1, has been shown to be a target epitope of cytotoxic lymphocytes (CTL) that preferentially lyse myeloid leukemia over normal bone marrow progenitors in vitro. The amount of CTL lysis correlates with Pr3 overexpression in the target cells. Detection of immunity to PR1 in normal donors and some patients with myeloid leukemia strongly implies that patient's own leukemia cells can act as a source of immunizing protein and begs the issue of whether existent immune responses to PR1 play any role in slowing leukemia progression and whether boosting of immune responses can offer any therapeutic benefit. The current NEW INVESTIGATOR proposal will assess the clinical importance of immune responses to PR1 peptide, evaluate a PR1 peptide-based tumor vaccine in patients with myeloid leukemia, and since Pr1 is the first tissue-restricted epitope identified, will investigate other unique HLA-A2-associated Pr3 peptides as leukemic-specific epitopes for CTL. To investigate the clinical significance of immune responses to PR1, CTL precursor (CTLP) frequency against PR1 will be determined in patients with CML, AML and their normal marrow donors before and after BMT using limiting dilution analysis and by using a fluorescence-tagged PR1-tetramer to directly label PR1-specific CTL. Pr3 expression in leukemia and the surface phenotype of leukemia and PR1-specific CTL will be examined and correlated to CTLP frequency and clinical outcomes. To investigate whether an immune response to PR1 can be boosted, a phase I/II study (NCI study number T98-0017, Molldrem P.I.) of PR1 peptide-based vaccine with incomplete Freund's adjuvant (IFA) will be conducted in patients with CML, AML, and myelodysplastic syndrome. The University of Texas M. D. Anderson Cancer Center has approved the investigation, and NCI will supply GMP quality PR1 peptide and IFA. Immune responses to the vaccine will be determined by LDA of CTLP and by analyzing the number of PR1-specific CTL with the fluorescent PR1-tetramer and will be correlated to clinical response and percent of leukemia blasts in bone marrow. Lastly, other synthetic HLA-A2-associated peptides from Pr3 will be investigated for their potential to elicit peptide-specific CTL from donor PBMC in vitro and then tested for ability to lyse myeloid leukemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anit-PR1 Immune Therapy for Myeloid Leukemia
Cord Blood T Cell Therapy for Myeloid Malignancies
PR1-specific CB T cells for Patients with Myeloid Malignancies
Cord Blood T Cell Therapy for Myeloid Malignancies
海外基金